Tusamitamab Ravtansine

瑞沃特赛妥单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTusamitamab Ravtansine
Drug Alias NameMaytansin-loaded anti-CEACAM5 mAb(Immunogen)SAR-408701IBI-126
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPDB linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonistsTubulin polymerisation inhibitors
TargetsCarcinoembryonic antigen related cell adhesion molecule 5Tubulin
Therapy Area/IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungLung Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[29] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesImmunogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiSanofi-Aventis Deutschland GmbhSanofi-Aventis Recherche & Developpement +[5] 
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungLung Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG